These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Regadenoson in the detection of coronary artery disease. Buhr C; Gössl M; Erbel R; Eggebrecht H Vasc Health Risk Manag; 2008; 4(2):337-40. PubMed ID: 18561509 [TBL] [Abstract][Full Text] [Related]
4. Randomized, controlled dose-ranging study of the selective adenosine A2A receptor agonist binodenoson for pharmacological stress as an adjunct to myocardial perfusion imaging. Udelson JE; Heller GV; Wackers FJ; Chai A; Hinchman D; Coleman PS; Dilsizian V; DiCarli M; Hachamovitch R; Johnson JR; Barrett RJ; Gibbons RJ Circulation; 2004 Feb; 109(4):457-64. PubMed ID: 14734517 [TBL] [Abstract][Full Text] [Related]
5. Effects of adenosine and a selective A2A adenosine receptor agonist on hemodynamic and thallium-201 and technetium-99m-sestaMIBI biodistribution and kinetics. Mekkaoui C; Jadbabaie F; Dione DP; Meoli DF; Purushothaman K; Belardinelli L; Sinusas AJ JACC Cardiovasc Imaging; 2009 Oct; 2(10):1198-208. PubMed ID: 19833310 [TBL] [Abstract][Full Text] [Related]
6. Regadenoson: review of its established role in myocardial perfusion imaging and emerging applications. Palani G; Ananthasubramaniam K Cardiol Rev; 2013; 21(1):42-8. PubMed ID: 22643345 [TBL] [Abstract][Full Text] [Related]
7. Myocardial perfusion imaging laboratory efficiency with the use of regadenoson compared to adenosine and dipyridamole. Friedman M; Spalding J; Kothari S; Wu Y; Gatt E; Boulanger L J Med Econ; 2013; 16(4):449-60. PubMed ID: 23363331 [TBL] [Abstract][Full Text] [Related]
8. [Regadenoson as a new stress agent in myocardial perfusion imaging. Initial experience in The Netherlands]. Jager PL; Buiting M; Mouden M; Oostdijk AH; Timmer J; Knollema S Rev Esp Med Nucl Imagen Mol; 2014; 33(6):346-51. PubMed ID: 24862658 [TBL] [Abstract][Full Text] [Related]
9. Patient- and clinician-reported satisfaction with pharmacological stress agents for single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI). Hudgens S; Breeze J; Spalding J J Med Econ; 2013; 16(6):828-34. PubMed ID: 23614479 [TBL] [Abstract][Full Text] [Related]
10. Myocardial stress perfusion magnetic resonance: initial experience in a pediatric and young adult population using regadenoson. Noel CV; Krishnamurthy R; Moffett B; Krishnamurthy R Pediatr Radiol; 2017 Mar; 47(3):280-289. PubMed ID: 28035425 [TBL] [Abstract][Full Text] [Related]
11. Advances in pharmacologic stress agents: focus on regadenoson. Johnson SG; Peters S J Nucl Med Technol; 2010 Sep; 38(3):163-71. PubMed ID: 20724531 [TBL] [Abstract][Full Text] [Related]
12. Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans. Lieu HD; Shryock JC; von Mering GO; Gordi T; Blackburn B; Olmsted AW; Belardinelli L; Kerensky RA J Nucl Cardiol; 2007 Jul; 14(4):514-20. PubMed ID: 17679059 [TBL] [Abstract][Full Text] [Related]
13. Regadenoson versus dipyridamole hyperemia for cardiac PET imaging. Johnson NP; Gould KL JACC Cardiovasc Imaging; 2015 Apr; 8(4):438-447. PubMed ID: 25797122 [TBL] [Abstract][Full Text] [Related]
14. Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results. Cerqueira MD; Nguyen P; Staehr P; Underwood SR; Iskandrian AE; JACC Cardiovasc Imaging; 2008 May; 1(3):307-16. PubMed ID: 19356442 [TBL] [Abstract][Full Text] [Related]
15. ST Segment Elevation ECG Changes During Pharmacologic Stress With Regadenoson. Qamruddin S; Huang HW; Mehra A; Bonyadlou S; Yoon AJ Clin Nucl Med; 2016 Jan; 41(1):62-4. PubMed ID: 26447370 [TBL] [Abstract][Full Text] [Related]
16. An example of the clinical selectivity of regadenoson for the A2a adenosine receptor. Miyamoto MI; Clarke KA; Thomas GS; Belardinelli L Am Heart Hosp J; 2009; 7(2):E118-21. PubMed ID: 20354957 [No Abstract] [Full Text] [Related]
17. Regadenoson-stress myocardial CT perfusion and single-photon emission CT: rationale, design, and acquisition methods of a prospective, multicenter, multivendor comparison. Cury RC; Kitt TM; Feaheny K; Akin J; George RT J Cardiovasc Comput Tomogr; 2014; 8(1):2-12. PubMed ID: 24314823 [TBL] [Abstract][Full Text] [Related]
18. Regadenoson versus Dipyridamole: A Comparison of the Frequency of Adverse Events in Patients Undergoing Myocardial Perfusion Imaging. Amer KA; Hurren JR; Edwin SB; Cohen G Pharmacotherapy; 2017 Jun; 37(6):657-661. PubMed ID: 28475259 [TBL] [Abstract][Full Text] [Related]
19. Hemodynamic response, arrhythmic risk, and overall safety of regadenoson as a pharmacologic stress agent for myocardial perfusion imaging in chronic obstructive pulmonary disease and bronchial asthma patients. Husain Z; Palani G; Cabrera R; Karthikeyan AS; Dhanalakota S; Pathmanathan S; Jacobsen G; Ananthasubramaniam K Int J Cardiovasc Imaging; 2012 Oct; 28(7):1841-9. PubMed ID: 22200931 [TBL] [Abstract][Full Text] [Related]
20. Current methods of pharmacologic stress testing and the potential advantages of new agents. Botvinick EH J Nucl Med Technol; 2009 Mar; 37(1):14-25. PubMed ID: 19258260 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]